AbbVie ABBV

NYS: ABBV | ISIN: US00287Y1091   16/10/2026
285,42 USD (+0,71%)
(+0,71%)   16/10/2026
Grafiek AbbVie Inc. Grafiek AbbVie Inc.
vrijdag 30 oktober 2026, 12:00
Kwartaalcijfers (3de kwartaal)

AbbVie Inc. in het nieuws

17 oktober 2026 · SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 · Persbericht

13 oktober 2026 · AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease · Persbericht

11 oktober 2026 · New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease · Persbericht

7 oktober 2026 · AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC · Persbericht

5 oktober 2026 · AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma · Persbericht

1 oktober 2026 · AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo · Persbericht

1 oktober 2026 · AbbVie to Host Third-Quarter 2026 Earnings Conference Call · Persbericht

30 september 2026 · AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 · Persbericht

30 september 2026 · AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 · Persbericht

30 september 2026 · AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress · Persbericht

Profiel AbbVie Inc.

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.abbvie.com

Hoofdzetel: North Chicago, Illinois vlag Verenigde Staten

Mijn selecties